SCHEDULE: Venrock Entities Report 4.2% Stake in Artiva Biotherapeutics

Several Venrock-affiliated entities and individuals have disclosed a combined beneficial ownership of 4.2% of Artiva Biotherapeutics, Inc.'s common stock as of June 30, 2026.

Summary

• The filing reports that Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Koh collectively beneficially own 2,043,596 shares of Artiva Biotherapeutics, Inc. common stock.
• This ownership stake represents 4.2% of the company's outstanding common stock as of June 30, 2026.
• The reporting persons are considered a group for the purposes of this filing.
• The filing is an amendment (Amendment No. 1) to a previous Schedule 13G filing.
• The date of the event requiring this filing is June 30, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, reflecting a significant but not controlling stake in Artiva Biotherapeutics, Inc. by established healthcare investors.

Positives

• Significant investment by established healthcare capital partners (Venrock entities) indicates confidence in Artiva Biotherapeutics' potential.
• The reporting persons collectively hold a substantial minority stake (4.2%), suggesting a notable interest in the company's performance.

Negatives

• The filing does not contain any negative financial or operational information about Artiva Biotherapeutics itself, as it is a disclosure of ownership by external parties.

Risks

• Potential for increased market activity or influence by the reporting group, which could impact stock price volatility.
• The nature of the investment by venture capital and healthcare capital partners implies a focus on growth and potential future strategic actions, which may or may not align with all existing shareholders' interests.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Artiva Biotherapeutics, Inc. regarding its future performance.

Industry Context

StockSavvy.ai notes that significant stakes held by specialized healthcare capital firms like Venrock often signal a belief in the target company's technology, market position, or growth trajectory within the biotechnology sector.

Stakeholder Impact

• Shareholders: The increased visibility from a significant investment by Venrock entities may attract further investor interest or signal potential strategic developments.
• Management and Board of Directors: May face increased scrutiny or engagement from a substantial minority shareholder group.

Next Steps

• The reporting persons will continue to monitor their investment in Artiva Biotherapeutics, Inc.
• Further amendments to this Schedule 13G may be filed if there are changes in beneficial ownership or other reportable events.

Key Dates

Keywords

Artiva Biotherapeutics, Schedule 13G, Venrock Healthcare Capital Partners, Beneficial Ownership, Common Stock, Investment Disclosure, Healthcare Capital